Lucia Carril-Ajuria, Pernelle Lavaud, Cecile Dalban, Sylvie Negrier, Gwénaëlle Gravis, Robert J Motzer, Christine Chevreau, Nizar M Tannir, Stéphane Oudard, David F McDermott, Brigitte Laguerre, Hans J Hammers, Philippe Barthelemy, Elizabeth R Plimack, Delphine Borchiellini, Marine Gross-Goupil, Ruiyun Jiang, Chung-Wei Lee, Heshani de Silva, Brian I Rini, Bernard Escudier, Laurence Albigès
BACKGROUND: The Lung Immune Prognostic Index (LIPI) is associated with immune checkpoint inhibitors (ICI) outcomes across different solid tumors, particularly in non-small cell lung cancer. Data regarding the prognostic and/or predictive role of LIPI in metastatic renal cell carcinoma (mRCC) are still scarce. The aim of this study was to evaluate whether LIPI could be predictive of survival in mRCC patients. METHODS: We used patient level data from three different prospective studies (NIVOREN trial: nivolumab; TORAVA trial: VEGF/VEGFR-targeted therapy (TT); CheckMate 214: nivolumab-ipilimumab vs sunitinib)...
April 8, 2024: European Journal of Cancer